Peptide–drug conjugate-based novel molecular drug delivery system in cancer

药品 药物输送 结合 药理学 肽 化学 医学 靶向给药 生物化学 数学 数学分析 有机化学
作者
Yishen Zhu,Kexing Tang,Jiayi Lv
出处
期刊:Trends in Pharmacological Sciences [Elsevier BV]
卷期号:42 (10): 857-869 被引量:142
标识
DOI:10.1016/j.tips.2021.07.001
摘要

A single peptide–drug conjugate molecule achieves multiple biological functions, which is proposed as a novel drug delivery system, the molecular drug delivery system. Recently, peptide–drug conjugates have been introduced as potential diagnostics and anticancer drugs in the clinic. Aminopeptidase N, integrins, the somatostatin receptor, and several other receptors are major molecular targeting receptors for current peptide–drug conjugate-based molecular drug delivery systems. Solving the problem of oral administration will greatly promote the development of peptide–drug conjugate molecular drug delivery systems. Drug delivery systems are generally believed to comprise drugs and excipients. A peptide–drug conjugate is a single molecule that can simultaneously play multiple roles in a drug delivery system, such as in vivo drug distribution, targeted release, and bioactivity functions. This molecule can be regarded as an integrated drug delivery system, so it is called a molecular drug delivery system. In the context of cancer therapy, a peptide–drug conjugate comprises a tumor-targeting peptide, a payload, and a linker. Tumor-targeting peptides specifically identify membrane receptors on tumor cells, improve drug-targeted therapeutic effects, and reduce toxic and side effects. Payloads with bioactive functions connect to tumor-targeting peptides through linkers. In this review, we explored ongoing clinical work on peptide–drug conjugates targeting various receptors. We discuss the binding mechanisms of tumor-targeting peptides and related receptors, as well as the limiting factors for peptide–drug conjugate-based molecular drug delivery systems. Drug delivery systems are generally believed to comprise drugs and excipients. A peptide–drug conjugate is a single molecule that can simultaneously play multiple roles in a drug delivery system, such as in vivo drug distribution, targeted release, and bioactivity functions. This molecule can be regarded as an integrated drug delivery system, so it is called a molecular drug delivery system. In the context of cancer therapy, a peptide–drug conjugate comprises a tumor-targeting peptide, a payload, and a linker. Tumor-targeting peptides specifically identify membrane receptors on tumor cells, improve drug-targeted therapeutic effects, and reduce toxic and side effects. Payloads with bioactive functions connect to tumor-targeting peptides through linkers. In this review, we explored ongoing clinical work on peptide–drug conjugates targeting various receptors. We discuss the binding mechanisms of tumor-targeting peptides and related receptors, as well as the limiting factors for peptide–drug conjugate-based molecular drug delivery systems. a chemotherapy medication used to treat chronic lymphocytic leukemia (CLL), Hodgkin lymphoma, and non-Hodgkin lymphoma. the rate of application of a dose, which means quantity (in units of energy/mass) in the fields of nutrition, and medicine, although in common and imprecise usage the words are sometimes used synonymously. formulation technologies for transporting active pharmaceutical ingredients in the body as needed to safely achieve the desired therapeutic or diagnostic effects. engineered technologies that use nanoscale particles for the targeted delivery and controlled release of active pharmaceutical ingredients. gives companies researching cures for rare diseases a 7-year window of tax reductions and the exclusive right to develop a cure for a specific condition. active pharmaceutical ingredients, which can be effectively used for diagnosis/treatment in patients. a small, protein-like chain designed to mimic a peptide. tomography in which a computer-generated image of a biological activity in the body is produced through the detection of gamma-rays that are emitted when introduced radionuclides decay and release positrons. a peptide hormone that regulates the endocrine system and affects neurotransmission and cell proliferation via interaction with G protein-coupled somatostatin receptors and inhibition of the release of numerous secondary hormones. a short peptide, typically in an α-helical conformation, that is constrained by a synthetic brace as a staple.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
慕青的应助被蜉蝣采纳,获得10
1秒前
zzz发布了新的文献求助10
1秒前
shn发布了新的文献求助10
2秒前
kkk发布了新的文献求助10
2秒前
0飝0完成签到,获得积分10
3秒前
谷兵辽发布了新的文献求助10
3秒前
半分青完成签到,获得积分10
3秒前
3秒前
绿豆酥发布了新的文献求助10
4秒前
ming完成签到,获得积分10
4秒前
4秒前
5秒前
5秒前
清冷渊完成签到 ,获得积分10
6秒前
hotcas完成签到,获得积分0
6秒前
牧青发布了新的文献求助10
7秒前
Marybaby完成签到,获得积分10
8秒前
虚幻中蓝发布了新的文献求助10
8秒前
TTOM发布了新的文献求助10
9秒前
话梅糖发布了新的文献求助10
9秒前
Lynette完成签到 ,获得积分0
10秒前
笨笨山芙的应助被熊猫海采纳,获得20
10秒前
秋水仙碱完成签到,获得积分10
10秒前
研友_VZG7GZ的应助被kkk采纳,获得10
11秒前
11秒前
11秒前
Levieus完成签到,获得积分10
12秒前
劲凉王完成签到,获得积分10
12秒前
李李完成签到,获得积分10
12秒前
12秒前
13秒前
dailixin完成签到 ,获得积分10
13秒前
SciGPT的应助被jimiha采纳,获得10
13秒前
14秒前
大模型的应助被Derive采纳,获得10
14秒前
TTOM完成签到,获得积分10
14秒前
14秒前
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Agyptische Geschichte der 21.30. Dynastie 510
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8191812
求助须知:如何正确求助?哪些是违规求助? 9578503
关于积分的说明 21859856
捐赠科研通 7791184
什么是DOI,文献DOI怎么找? 3436733
关于科研通互助平台的介绍 2560447
邀请新用户注册赠送积分活动 2483502